Skip to main content
Log in

Treatment of immunoglobulin light chain amyloidosis

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Therapies shown to be effective are based on alkylators, dexamethasone, or combinations of an alkylator and steroids. In the past 5 years, novel agents previously shown to be effective in multiple myeloma (eg, thalidomide, lenalidomide, and bortezomib) have been shown to have efficacy in the management of AL amyloidosis. Predictors of outcome include the serum brain natriuretic peptide, the number of organs involved, and the severity of cardiac involvement detected by echocardiography. Virtually all patients are candidates for a trial of therapy, and it is possible to find a nontoxic regimen that can be administered to virtually any patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Comenzo RL: Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 2007, 5:179–187.

    PubMed  CAS  Google Scholar 

  2. Miyazaki D, Yazaki M, Gono T, et al.: AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report. Amyloid 2008, 15:125–128.

    Article  PubMed  CAS  Google Scholar 

  3. Obici L, Perfetti V, Palladini G, et al.: Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005, 1753:11–22.

    PubMed  CAS  Google Scholar 

  4. Ionescu-Zanetti C, Khurana R, Gillespie JR, et al.: Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci U S A 1999, 96:13175–13179.

    Article  PubMed  CAS  Google Scholar 

  5. Brenner DA, Jain M, Pimentel DR, et al.: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004, 94:1008–1010.

    Article  PubMed  CAS  Google Scholar 

  6. Kingsbury JS, Laue TM, Klimtchuk ES, et al.: The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation. J Biol Chem 2008, 283:11887–11896.

    Article  PubMed  CAS  Google Scholar 

  7. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, et al.: Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007, 48:865–872.

    Article  PubMed  CAS  Google Scholar 

  8. Buxbaum J: Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. J Clin Invest 1986, 78:798–806.

    Article  PubMed  CAS  Google Scholar 

  9. Cohen AS, Rubinow A, Anderson JJ, et al.: Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987, 82:1182–1190.

    Article  PubMed  CAS  Google Scholar 

  10. Brandwein SR, Sipe JD, Skinner M, Cohen AS: Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation. Lab Invest 1985, 52:319–325.

    PubMed  CAS  Google Scholar 

  11. Schwartz RS, Cohen JR, Schrier SL: Therapy of primary amyloidosis with melphalan and prednisone. Arch Intern Med 1979, 139:1144–1147.

    Article  PubMed  CAS  Google Scholar 

  12. Comenzo RL, Vosburgh E, Falk RH, et al.: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662–3670.

    PubMed  CAS  Google Scholar 

  13. Moreau P, Leblond V, Bourquelot P, et al.: Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998, 101:766–769.

    Article  PubMed  CAS  Google Scholar 

  14. Seldin DC, Anderson JJ, Sanchorawala V, et al.: Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004, 104:1888–1893.

    Article  PubMed  CAS  Google Scholar 

  15. Skinner M, Sanchorawala V, Seldin DC, et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85–93.

    PubMed  CAS  Google Scholar 

  16. Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002, 99:4276–4282.

    Article  PubMed  CAS  Google Scholar 

  17. Goodman HJ, Gillmore JD, Lachmann HJ, et al.: Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006, 134:417–425.

    Article  PubMed  Google Scholar 

  18. Gertz MA, Lacy MQ, Dispenzieri A, et al.: Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002, 113:549–555.

    Article  PubMed  CAS  Google Scholar 

  19. Saba N, Sutton D, Ross H, et al.: High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999, 24:853–855.

    Article  PubMed  CAS  Google Scholar 

  20. Kumar S, Dispenzieri A, Lacy MQ, et al.: High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001, 28:381–385.

    Article  PubMed  CAS  Google Scholar 

  21. Capizzi SA, Kumar S, Huneke NE, et al.: Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:1299–1303.

    Article  PubMed  CAS  Google Scholar 

  22. Gertz MA, Lacy MQ, Dispenzieri A, et al.: Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004, 34:1025–1031.

    Article  PubMed  CAS  Google Scholar 

  23. Leung N, Dispenzieri A, Lacy MQ, et al.: Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007, 2:440–444.

    Article  PubMed  Google Scholar 

  24. Dispenzieri A, Lacy MQ, Katzmann JA, et al.: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006, 107:3378–3383.

    Article  PubMed  CAS  Google Scholar 

  25. Gertz MA, Lacy MQ, Gastineau DA, et al.: Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000, 26:963–969.

    Article  PubMed  CAS  Google Scholar 

  26. Vesole DH, Pérez WS, Akasheh M, et al.; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research: High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006, 81:880–888.

    Article  PubMed  Google Scholar 

  27. Gertz M, Lacy M, Dispenzieri A, et al.: Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008, 49:36–41.

    Article  PubMed  CAS  Google Scholar 

  28. Gertz MA, Lacy MQ, Dispenzieri A, et al.: Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007, 92:1415–1418.

    Article  PubMed  Google Scholar 

  29. Jaccard A, Moreau P, Leblond V, et al.: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083–1093.

    Article  PubMed  CAS  Google Scholar 

  30. Kumar S, Dispenzieri A, Gertz MA: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008, 358:91, author reply 92–93.

    Article  PubMed  CAS  Google Scholar 

  31. Gertz MA, Lacy MQ, Dispenzieri A, et al.: Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007, 39:605–611.

    Article  PubMed  CAS  Google Scholar 

  32. Comenzo RL: Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006, 7:182–185.

    Article  PubMed  CAS  Google Scholar 

  33. Gertz MA, Lacy MQ, Dispenzieri A, et al.: Transplantation for amyloidosis. Curr Opin Oncol 2007, 19:136–141.

    Article  PubMed  CAS  Google Scholar 

  34. Horne MK 3rd: Letter: Improvement in amyloidosis. Ann Intern Med 1975, 83:281–282.

    PubMed  Google Scholar 

  35. Corkery J, Bern MM, Tullis JL: Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy. Lancet 1978, 2:425–426.

    Article  PubMed  CAS  Google Scholar 

  36. Gertz MA, Kyle RA: Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990, 150:629–633.

    Article  PubMed  CAS  Google Scholar 

  37. Gertz MA, Lacy MQ, Lust JA, et al.: Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica 2008, 93:1402–1406.

    Article  PubMed  CAS  Google Scholar 

  38. Kyle RA, Greipp PR: Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978, 52:818–827.

    PubMed  CAS  Google Scholar 

  39. Kyle RA, Greipp PR: Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983, 58:665–683.

    PubMed  CAS  Google Scholar 

  40. Gertz MA, Kyle RA, Greipp PR: Response rates and survival in primary systemic amyloidosis. Blood 1991, 77:257–262.

    PubMed  CAS  Google Scholar 

  41. Grogan M, Gertz MA, Kyle RA, Tajik AJ: Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2000, 85:664–665, A611.

    Article  PubMed  CAS  Google Scholar 

  42. Kyle RA, Gertz MA, Greipp PR, et al.: Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999, 93:1062–1066.

    PubMed  CAS  Google Scholar 

  43. Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202–1207.

    Article  PubMed  CAS  Google Scholar 

  44. Skinner M, Anderson J, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996, 100:290–298.

    Article  PubMed  CAS  Google Scholar 

  45. Sanchorawala V, Wright DG, Seldin DC, et al.: Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002, 117:886–889.

    Article  PubMed  CAS  Google Scholar 

  46. Tazawa K, Matsuda M, Yoshida T, et al.: Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients. Intern Med 2008, 47:1517–1522.

    Article  PubMed  Google Scholar 

  47. Sezer O, Schmid P, Shweigert M, et al.: Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999, 23:967–969.

    Article  PubMed  CAS  Google Scholar 

  48. van Gameren II, Hazenberg BP, Jager PL, et al.: AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002, 9:165–174.

    PubMed  Google Scholar 

  49. Lachmann HJ, Gallimore R, Gillmore JD, et al.: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003, 122:78–84.

    Article  PubMed  CAS  Google Scholar 

  50. Dhodapkar MV, Jagannath S, Vesole D, et al.: Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997, 27:351–356.

    PubMed  CAS  Google Scholar 

  51. Gertz MA, Lacy MQ, Lust JA, et al.: Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999, 16:104–109.

    Article  PubMed  CAS  Google Scholar 

  52. Gertz MA, Lacy MQ, Lust JA, et al.: Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 1999, 61:115–119.

    Article  PubMed  CAS  Google Scholar 

  53. Palladini G, Anesi E, Perfetti V, et al.: A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001, 113:1044–1046.

    Article  PubMed  CAS  Google Scholar 

  54. Dhodapkar MV, Hussein MA, Rasmussen E, et al.: Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004, 104:3520–3526.

    Article  PubMed  CAS  Google Scholar 

  55. Palladini G, Perfetti V, Obici L, et al.: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2936–2938.

    Article  PubMed  CAS  Google Scholar 

  56. Palladini G, Russo P, Nuvolone M, et al.: Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007, 110:787–788.

    Article  PubMed  CAS  Google Scholar 

  57. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN: Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis [abstract 755]. Blood (ASH Annual Meeting Abstracts) 2004, 104.

  58. Seldin DC, Choufani EB, Dember LM, et al.: Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003, 3:241–246.

    Article  PubMed  CAS  Google Scholar 

  59. Dispenzieri A, Lacy MQ, Rajkumar SV, et al.: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003, 10:257–261.

    PubMed  CAS  Google Scholar 

  60. Palladini G, Perfetti V, Perlini S, et al.: The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005, 105:2949–2951.

    Article  PubMed  CAS  Google Scholar 

  61. Wechalekar AD, Goodman HJ, Lachmann HJ, et al.: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007, 109:457–464.

    Article  PubMed  CAS  Google Scholar 

  62. Palladini G, Russo P, Lavatelli F, et al.: Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009, 88:347–350.

    Article  PubMed  CAS  Google Scholar 

  63. Sanchorawala V, Wright DG, Rosenzweig M, et al.: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007, 109:492–496.

    Article  PubMed  CAS  Google Scholar 

  64. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al.: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007, 109:465–470.

    Article  PubMed  CAS  Google Scholar 

  65. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al.: Long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:1737.

    Google Scholar 

  66. Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A: Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006, 142:1298–1302.

    Article  PubMed  CAS  Google Scholar 

  67. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM: Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008, 49:1108–1115.

    Article  PubMed  CAS  Google Scholar 

  68. Sterz J, von Metzler I, Hahne JC, et al.: The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008, 17:879–895.

    Article  PubMed  CAS  Google Scholar 

  69. Dimopoulos MA, Kastritis E, Rosinol L, et al.: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22:1485–1493.

    Article  PubMed  CAS  Google Scholar 

  70. Sitia R, Palladini G, Merlini G: Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007, 92:1302–1307.

    Article  PubMed  CAS  Google Scholar 

  71. Fauble VS, Shah-Reddy I: Primary amyloidosis treated with bortezomib with a clinical and radiological response [abstract 5111]. Blood (ASH Annual Meeting Abstracts) 2006, 108.

  72. Wechalekar AD, Gillmore JD, Lachmann HJ, et al.: Efficacy and safety of bortezomib in systemic AL amyloidosis-a preliminary report [abstract 129]. Blood (ASH Annual Meeting Abstracts) 2006, 108.

  73. Wechalekar AD, Lachmann HJ, Offer M, et al.: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008, 93:295–298.

    Article  PubMed  CAS  Google Scholar 

  74. Reece DESV, Hegenbart U, Merlini G, et al.: Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). J Clin Oncol 2007, 25:453s.

    Google Scholar 

  75. Kastritis E, Anagnostopoulos A, Roussou M, et al.: Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007, 92:1351–1358.

    Article  PubMed  CAS  Google Scholar 

  76. Wall JS, Kennel SJ, Paulus M, et al.: Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med 2006, 47:2016–2024.

    PubMed  CAS  Google Scholar 

  77. Solomon A, Weiss DT, Wall JS: Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 2003, 18:853–860.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Morie A. Gertz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M.A., Zeldenrust, S.R. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep 4, 91–98 (2009). https://doi.org/10.1007/s11899-009-0013-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-009-0013-6

Keywords

Navigation